checkAd

    DGAP-News  623  0 Kommentare Press Release: 4SC presents new immunotherapeutic activity data of its epigenetic cancer drug resminostat at the ECCO ITOC conference 2015 - Seite 4


    targeted, small-molecule drugs for treating diseases with high unmet
    medical needs in various cancer and autoimmune indications. These drugs are
    intended to provide innovative treatment options that are more tolerable
    and efficacious than existing therapies, and provide a better quality of
    life. The Company's pipeline comprises promising products that are in
    various stages of clinical development. 4SC's aim is to generate future
    growth and enhance its enterprise value by entering into partnerships with
    leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a
    headcount of 66 employees (57 FTEs) at 31 December 2014. 4SC AG has been
    listed on the Prime Standard of the Frankfurt Stock Exchange since December
    2005.

    Cautionary statement regarding forward-looking statements
    This press release contains certain forward-looking statements. Any
    forward-looking statement applies only on the date of this press release.
    By their nature, forward-looking statements are subject to a number of
    known and unknown risks and uncertainties that may or may not occur in the
    future and as a result of which the actual results and performance may
    differ substantially from the expected future results or performance
    expressed or implied in the forward looking statements. No warranties or
    representations are made as to the accuracy, achievement or reasonableness
    of such statements, estimates or projections, and 4SC AG has no obligation
    to update any such information or to correct any inaccuracies herein or
    omission herefrom which may become apparent.

    For more information please visit www.4sc.com or contact:

    4SC AG
    Jochen Orlowski, Corporate Communications & Investor Relations
    jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

    MC Services
    Katja Arnold, Michelle Kremer
    katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

    The Trout Group
    Chad Rubin
    crubin(at)troutgroup.com, Tel.: +1-646-378-2947



    ---------------------------------------------------------------------

    26.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: 4SC AG
    Am Klopferspitz 19a
    82152 Martinsried
    Germany
    Phone: +49 (0)89 7007 63-0
    Fax: +49 (0)89 7007 63-29
    E-mail: public@4sc.com
    Internet: www.4sc.de
    ISIN: DE0005753818
    WKN: 575381
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
    Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    337639 26.03.2015
    Seite 4 von 4



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Press Release: 4SC presents new immunotherapeutic activity data of its epigenetic cancer drug resminostat at the ECCO ITOC conference 2015 - Seite 4 DGAP-News: 4SC AG / Key word(s): Research Update Press Release: 4SC presents new immunotherapeutic activity data of its epigenetic cancer drug resminostat at the ECCO ITOC conference 2015 26.03.2015 / 07:30 …